Clinical Trials

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma


Study ID
Glenmark GBR 1342-101

NCT Number
NCT03309111 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0424

Principle Investigator
Dr. David Vesole

Phase
I

Sponsor
Glenmark Pharmaceuticals


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now